Latest On Swedish Orphan Biovitrum AB (publ) (BIOVF):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-25 15:38 EST | News | Apellis and Sobi to drop ALS candidate on Phase 2 setback | N/A |  |
| 2023-05-19 19:06 EST | News | Sobi's hemophilia A therapy gets review in EU | N/A | |
| 2023-04-29 15:13 EST | News | Swedish Orphan Biovitrum AB (publ) 2023 Q1 - Results - Earnings Call Presentation | N/A | |
| 2023-04-29 15:13 EST | News | Swedish Orphan Biovitrum AB (publ) (BIOVF) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-04-27 13:35 EST | News | Swedish Orphan Biovitrum AB Non-GAAP EPS of SEK3.60, revenue of SEK5.24B | N/A | |
| 2023-04-11 07:24 EST | News | Sanofi to get commercial control of RSV therapy nirsevimab in US, AstraZeneca to record $0.7B gain | N/A | |
| 2023-03-21 14:12 EST | News | Selecta surges ~20% as gout drug SEL-212 meets main goal in 2 phase 3 trials | N/A | |
| 2023-02-24 12:22 EST | News | Sanofi wins FDA nod for once-weekly bleeding disorder therapy | N/A | |
| 2023-02-21 05:42 EST | News | AstraZeneca, Sanofi's RSV therapy Beyfortus for infants shows 'consistent protection' in trial | N/A | |
| 2023-02-09 05:31 EST | News | Swedish Orphan Biovitrum AB (publ) (BIOVF) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-02-08 16:28 EST | News | Swedish Orphan Biovitrum AB reports Q4 earnings; issues FY23 soft guidance | N/A | |
| 2022-11-09 17:29 EST | News | Sobi wins FDA nod for COVID-19 therapy | N/A | |
| 2022-10-29 14:52 EST | News | Swedish Orphan Biovitrum AB (publ) (BIOVF) Q3 2022 Earnings Call Transcript | N/A | |
| 2022-10-29 14:52 EST | News | Swedish Orphan Biovitrum AB (publ) 2022 Q3 - Results - Earnings Call Presentation | N/A | |
| 2022-10-27 19:07 EST | News | Swedish Orphan Biovitrum AB GAAP EPS of SEK 1.52, revenue of SEK 4B | N/A | |
| 2022-07-20 01:51 EST | News | Swedish Orphan Biovitrum AB (BIOVF) CEO Guido Oelkers on Q2 2022 Results Earnings Call Transcript | N/A | |
| 2022-07-19 11:10 EST | News | Swedish Orphan Biovitrum AB (publ) 2022 Q2 - Results - Earnings Call Presentation | N/A | |
| 2022-07-19 11:10 EST | News | Swedish Orphan Biovitrum AB Non-GAAP EPS of -SEK0.91, revenue of SEK3.87M misses by SEK352.44M | N/A | |
| 2022-07-08 12:42 EST | News | Sobi to pay ADC Therapeutics $55M upfront to license Zynlonta in Europe, other regions | N/A | |
| 2022-04-30 11:21 EST | News | Swedish Orphan Biovitrum AB (BIOVF) CEO Guido Oelkers on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-04-29 17:47 EST | News | Swedish Orphan Biovitrum AB (publ) 2022 Q1 - Results - Earnings Call Presentation | N/A | |
| 2022-04-29 00:29 EST | News | Swedish Orphan Biovitrum AB Non-GAAP EPS of SEK 3.67, revenue of SEK 4.92B | N/A | |
| 2022-03-04 16:04 EST | News | Swedish Orphan Biovitrum AB (BIOVF) CEO Guido Oelkers on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-02-11 13:51 EST | News | Swedish Orphan Biovitrum AB (publ) 2021 Q4 - Results - Earnings Call Presentation | N/A | |
| 2022-02-10 20:31 EST | News | Swedish Orphan Biovitrum AB Non-GAAP EPS of SEK4.21, revenue of SEK4.9B | N/A | |
| 2021-12-15 23:34 EST | News | Apellis Pharma's Aspaveli OK'd in EU as Orphan Drug for treatment of PNH | N/A | |
| 2021-08-27 01:10 EST | News | Sobi targeted by Advent for a potential acquisition - Bloomberg | N/A | |
| 2021-07-22 14:19 EST | News | Apellis reports positive Empaveli data from late-stage study in rare blood disorder | N/A | |
| 2021-07-22 14:08 EST | News | Swedish Orphan Biovitrum AB reports Q2 results | N/A | |
| 2021-07-22 14:08 EST | News | Swedish Orphan Biovitrum AB (publ) 2021 Q2 - Results - Earnings Call Presentation | N/A | |
| 2021-07-22 14:07 EST | News | Swedish Orphan Biovitrum AB (publ) (BIOVF) CEO Guido Oelkers on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-05-04 11:14 EST | News | Swedish Orphan Biovitrum AB reports Q1 results | N/A | |
| 2021-03-18 10:30 EST | News | Phase 3 data shows Apellis blood disorder drug besting Alexion's Soliris | N/A | |
| 2021-02-20 05:22 EST | Financials | Company financials have been released. | Neutral | |
| 2021-02-19 20:39 EST | News | Swedish Orphan Biovitrum AB (publ) (BIOVF) CEO Guido Oelkers on Q4 2020 Results - Earnings Call Transcript | N/A | |
| 2021-02-19 02:42 EST | News | Swedish Orphan Biovitrum AB reports Q4 results | N/A | |
| 2021-02-19 02:41 EST | News | Swedish Orphan Biovitrum AB (publ) 2020 Q4 - Results - Earnings Call Presentation | N/A | |
| 2020-12-15 05:26 EST | News | Apellis remains a top pick at Baird after AstraZeneca/Alexion deal | N/A | |
| 2020-12-11 16:14 EST | News | European advisory group backs SOBI's Gilead's Doptelet in thrombocytopenia | N/A | |
| 2020-12-10 22:58 EST | News | Apellis, Sobi's pegcetacoplan shows positive action in rare blood disorder | N/A | |
| 2020-11-26 23:20 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-20 10:05 EST | News | Dosing underway for Apellis, Sobi's study of pegcetacoplan in muscle weakness | N/A | |
| 2020-11-13 17:11 EST | News | European advisory group affirms rejection of Swedish Orphan's Gamifant for rare inflammatory disorder | N/A | |
| 2020-11-08 02:21 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 18:42 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-02 05:45 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-01 09:37 EST | News | Apellis, Sobi inks licensing pact for systemic pegcetacoplan | N/A | |
| 2020-10-23 15:43 EST | News | Swedish Orphan Biovitrum AB (publ) 2020 Q3 - Results - Earnings Call Presentation | N/A | |
| 2020-10-23 15:43 EST | News | Swedish Orphan Biovitrum AB (BIOVF) CEO Guido Oelkers on Q3 2020 Results - Earnings Call Transcript | N/A | |
| 2020-10-22 11:59 EST | News | Swedish Orphan Biovitrum AB reports Q3 results | N/A | |
About Swedish Orphan Biovitrum AB (publ) (BIOVF):
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases. The company offers Alprolix for haemophilia B; Doptelet for chemotherapy induced thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. It also develops drug substance for ReFacto AF; BIVV001 for haemophilia A; BIVV0023 for haemophilia B; and Nirsevimab for respiratory syncytial virus. The company operates in Europe, North America, the Middle East, Russia, North Africa, and Asia. It has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.
General
- Name Swedish Orphan Biovitrum AB (publ)
- Symbol BIOVF
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 1,509
- Fiscal Year EndDecember
- Web URLhttp://www.sobi.com
View More
Valuation
- Trailing PE 14.75
- Forward PE 22.12
- Price/Sales (Trailing 12 Mt.) 2.82
- Price/Book (Most Recent Quarter) 2.32
- Enterprise Value Revenue 0.42
- Enterprise Value EBITDA 1.01
View More
Financials
- Most Recent Quarter 2020-12-31
- Profit Margin 21%
- Return on Assets 6%
- Return on Equity 17%
- Revenue Per Share $0
- Gross Profit 12.04 billion
- Quarterly Earnings Growth -6.3%
View More
Highlights
- Market Capitalization 4.87 billion
- PEG Ratio 34.18
View More
Share Statistics
- Shares Outstanding 294.9 million
- Shares Float 183.05 million
- % Held by Insiders <1%
- % Held by Institutions 72.62%
View More
Technicals
- Beta 0.78
- 52 Week High $26.05
- 52 Week Low $15.63
- 50 Day Moving Average 17.99
- 200 Day Moving Average 18.44
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Swedish Orphan Biovitrum AB (publ) (BIOVF) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Swedish Orphan Biovitrum AB (publ) (BIOVF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-12-31 | $2.97 billion | $0.61 | $1.07 | -42.75% |
| 2020-06-30 | 2020-09-30 | $3.07 billion | $0.10 | $1.69 | -93.86% |
| 2020-03-31 | 2020-06-30 | $N/A | $0.10 | $4.31 | -97.64% |
| 2019-12-31 | 2020-03-31 | $4.89 billion | $0.40 | $5.58 | -92.79% |
| 2019-09-30 | 2019-12-31 | $2.93 billion | $0.49 | $1.86 | -73.66% |
| 2019-06-30 | 2019-09-30 | $3.16 billion | $0.19 | $1.65 | -88.73% |
| 2019-03-31 | 2019-06-30 | $3.27 billion | $0.18 | $3.58 | -94.92% |
| 2018-12-31 | 2019-03-31 | $2.57 billion | $0.34 | $2.23 | -84.95% |
| 2018-09-30 | 2018-12-31 | $2.32 billion | $0.25 | $2.48 | -90.03% |
| 2018-06-30 | 2018-09-30 | $343.28 million | $0.26 | $1.91 | -86.45% |
| 2018-03-31 | 2018-06-30 | $1.96 billion | $0.28 | $1.46 | -80.65% |
| 2017-12-31 | 2018-03-31 | $1.87 billion | $0.23 | $1.15 | -80.2% |
| 2017-09-30 | 2017-12-31 | $1.6 billion | $0.16 | $1.10 | -85.35% |
| 2017-06-30 | 2017-09-30 | $1.64 billion | $0.15 | $0.83 | -82.25% |
| 2017-03-31 | 2017-06-30 | $0.12 | $0.70 | -83.39% | |
| 2016-12-31 | 2017-03-31 | $0.08 | $0.33 | -74.64% | |
| 2016-09-30 | 2016-12-31 | $0.03 | $0.18 | -83.28% | |
| 2016-06-30 | 2016-09-30 | $0.06 | $0.92 | -93.66% | |
| 2016-03-31 | 2016-06-30 | $0.13 | $1.23 | -89.64% | |
| 2015-12-31 | 2016-03-31 | $0.14 | -$0.01 | 1482% | |
| 2015-09-30 | 2015-12-31 | -$0.01 | $0.00 | ||
| 2015-06-30 | 2015-09-30 | $0.00 | -$0.07 | 103.14% | |
| 2015-03-31 | 2015-06-30 | $-0.00 | $0.20 | -100.6% | |
| 2014-12-31 | 2015-03-31 | $0.03 | -$0.22 | 114.77% | |
| 2014-09-30 | 2014-12-31 | -$0.01 | $0.08 | -111.38% | |
| 2014-06-30 | 2014-09-30 | $0.03 | $0.00 | ||
| 2014-03-31 | 2014-06-30 | $0.01 | $0.00 | ||
| 2013-12-31 | 2014-03-31 | -$0.19 | $0.00 | ||
| 2013-09-30 | 2013-12-31 | -$0.01 | $0.00 | ||
| 2013-06-30 | 2013-09-30 | -$0.03 | $0.00 | ||
| 2013-03-31 | 2013-06-30 | -$0.01 | $0.00 | ||
| 2012-12-31 | 2013-03-31 | -$0.01 | $0.00 | ||
| 2012-09-30 | 2012-12-31 | -$0.08 | $0.00 | ||
| 2012-06-30 | 2012-09-30 | -$0.03 | $0.00 | ||
| 2012-03-31 | 2012-06-30 | -$0.04 | $0.00 | ||
| 2011-12-31 | 2012-03-31 | $0.09 | $0.00 | ||
| 2011-09-30 | 2011-12-31 | $0.01 | $0.00 | ||
| 2011-06-30 | 2011-09-30 | -$0.02 | $0.00 | ||
| 2011-03-31 | 2011-06-30 | $0.08 | $0.00 | ||
| 2010-12-31 | 2011-03-31 | -$0.05 | $0.00 | ||
| 2010-09-30 | 2010-12-31 | -$0.01 | $0.00 |
Swedish Orphan Biovitrum AB (publ) (BIOVF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | 405 million | 345 million | N/A | 357 million |
| Income Before Tax | N/A | 366 million | 358 million | N/A | 1.76 billion |
| Selling General Administrative | N/A | 1.42 billion | 1000 million | N/A | 1.5 billion |
| Gross Profit | N/A | 2.34 billion | 2.38 billion | N/A | 3.83 billion |
| Ebit | N/A | 965 million | 882 million | N/A | 1.97 billion |
| Operating Income | N/A | 464 million | 540 million | N/A | 1.97 billion |
| Income Tax Expense | 434 million | 88 million | 75 million | 375 million | 402 million |
| Total Revenue | N/A | 2.97 billion | 3.07 billion | N/A | 4.89 billion |
| Cost of Revenue | N/A | 632 million | 689 million | N/A | 1.06 billion |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | -204 million |
| Net Income From Continuing Operations | N/A | 278 million | 283 million | N/A | 1.36 billion |
| Net Income Applicable to Common Shares | 1.5 billion | 278 million | 283 million | 1.18 billion | 1.36 billion |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | -124 million | N/A | N/A | N/A |
| Change to Liabilities | N/A | N/A | N/A | N/A | N/A |
| Total Cash Flow from Investing Activities | -1.29 billion | -124 million | -24 million | -8.74 billion | -4.05 billion |
| Net Borrowings | 802 million | -2.41 billion | -1.89 billion | 7.43 billion | 2.93 billion |
| Total Cash Flow from Financial Activities | N/A | N/A | N/A | 7.43 billion | 2.93 billion |
| Change to Operating Activities | -490 million | 1.38 billion | -16 million | -952 million | 22 million |
| Change in Cash | N/A | -621 million | N/A | -340 million | -112 million |
| Total Cash from Operating Activities | 443 million | 1.91 billion | 2 billion | 976 million | 995 million |
| Depreciation | N/A | 517 million | N/A | 472 million | 379 million |
| Other Cash Flow from Investing Activities | N/A | N/A | -1000000 | N/A | 1000000 |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Financing Activities | N/A | -1000000 | N/A | -1000000 | -1000000 |
| Change to Net Income | 154 million | -270 million | 328 million | 96 million | 52 million |
| Capital Expenditures | N/A | 124 million | N/A | 10 million | 10 million |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | 25.35 billion | 24.02 billion | N/A | 28.73 billion |
| Total Stockholder Equity | N/A | 18.78 billion | 18.62 billion | N/A | 16.93 billion |
| Other Current Liabilities | 5.75 billion | 4.37 billion | 4.72 billion | N/A | 4.96 billion |
| Total Assets | N/A | 44.13 billion | 42.64 billion | N/A | 45.66 billion |
| Common Stock | 20.21 billion | 18.78 billion | 18.62 billion | 18.65 billion | 16.93 billion |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | 7.19 billion | 7.25 billion | 6.36 billion | 6.67 billion | 6.53 billion |
| Other Assets | 611 million | 698 million | 1000000 | N/A | 1000000 |
| Cash | N/A | 164 million | 213 million | N/A | 737 million |
| Total Current Liabilities | 10.44 billion | 7 billion | 5.28 billion | N/A | 5.74 billion |
| Other Stockholder Equity | N/A | N/A | N/A | N/A | N/A |
| Property, Plant & Equipment | 534 million | 564 million | 594 million | 514 million | 518 million |
| Total Current Assets | 8.17 billion | 5.46 billion | 5.1 billion | N/A | 7.32 billion |
| Long Term Investments | N/A | N/A | N/A | N/A | 404 million |
| Net Tangible Assets | -18.59 billion | -18.46 billion | -17.74 billion | -19.36 billion | -20.48 billion |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | 10.76 billion | 12.02 billion | N/A | 16.14 billion |
| Inventory | 3.05 billion | 2.54 billion | 2.15 billion | N/A | 1.77 billion |
| Accounts Payable | 569 million | 414 million | 456 million | N/A | 681 million |
Swedish Orphan Biovitrum AB (publ) (BIOVF) Chart:
Swedish Orphan Biovitrum AB (publ) (BIOVF) News:
Below you will find a list of latest news for Swedish Orphan Biovitrum AB (publ) (BIOVF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Swedish Orphan Biovitrum AB (publ) (BIOVF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Swedish Orphan Biovitrum AB (publ) (BIOVF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|